Literature DB >> 11240752

The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer.

W. Schröder1, M. Zimny, C. Rudlowski, U. Büll, W. Rath.   

Abstract

We evaluated the clinical significance of 18F-FDG PET to detect malignant ovarian neoplasms and tumor spread. 40 patients (median age: 57.5 years) underwent laparotomy because of clinical suspicion of malignant ovarian tumors or recurrent disease. The results of the preoperatively performed PET were correlated with the postoperative histologic diagnosis and the intraoperatively assessed tumor spread. In 10 of 40 patients benign tumors were found, among which a tubo-ovarian abscess was the only one diagnosed as false positive. 4/30 malignant neoplasms did not originate from the coelomic epithelium, but all were correctly recognized as malignant tumors by PET, as was recurrent ovarian cancer in 12 patients. Out of 14 primary ovarian carcinomas, 2 borderline tumors and 1 well-differentiated adenocarcinoma FIGO stage I were not correctly identified. Considering the tumor type, sensitivity, and specificity were 90%, calculating for the positive and negative predictive value 96% and 75%, respectively, and 90% for the diagnostic accuracy. Those statistical parameters were slightly lower for PET detection of lymph node metastasis and peritoneal carcinomatosis. Although its diagnostic accuracy may vary depending on the clinical application, 18F-FDG PET is basically a suitable method for detecting ovarian malignancies, particularly in patients with relapsed ovarian carcinoma.

Entities:  

Year:  1999        PMID: 11240752     DOI: 10.1046/j.1525-1438.1999.09903.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.

Authors:  María José García-Velloso; Matías Jurado; Carolina Ceamanos; José Manuel Aramendía; María Puy Garrastachu; Guillermo López-García; José Angel Richter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-21       Impact factor: 9.236

Review 2.  A new dimension of FDG-PET interpretation: assessment of tumor biology.

Authors:  Thomas C Kwee; Sandip Basu; Babak Saboury; Valentina Ambrosini; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

3.  Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

Authors:  B Böhm; M Voth; J Geoghegan; H Hellfritzsch; A Petrovich; J Scheele; D Gottschild
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-06       Impact factor: 4.553

4.  [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.

Authors:  Sungeun Kim; June-Key Chung; Soon-Beom Kang; Moon-Hong Kim; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

5.  Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding.

Authors:  S Fanti; C Nanni; P Castellucci; M Farsad; L Rampin; M D Gross; G Mariani; D Rubello
Journal:  Cancer Imaging       Date:  2006-03-23       Impact factor: 3.909

6.  Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET.

Authors:  Yoshio Yoshida; Tetsuji Kurokawa; Tetuya Tsujikawa; Hidehiko Okazawa; Fumikazu Kotsuji
Journal:  J Ovarian Res       Date:  2009-06-16       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.